A Retrospective Study of Mortality Benefit Provided by Singl | 92330

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Retrospective Study of Mortality Benefit Provided by Single Dose COVID Vaccine at Society Level during Second Wave of COVID at A Zonal Hospital

Author(s): Vikas Srivastava, Ahijit Banerjee, Harjot Singh and Sanjaya Kumar Gupta*


Introduction: Since December 2019, the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic has caused high morbidity and mortality, with new variants rapidly spreading. Vaccines to prevent corona virus disease 2019 (Covid-19) have been developed with unprecedented speed.
Materials and Methods: An open, real-time, retrospective observational study was conducted at 167 Military Hospital, Pathankot. Data was available for 490 COVID 19 patients. The population of interest was 18-87 years old patients who were treated for moderate to severe COVID pneumonia irrespective of the vaccination status. Vaccination history was documented on admission. We also documented awareness regarding the name of covid-19 vaccine administered to the patients admitted in this hospital.
Results: Between 08 Dec 2020, and 20 Jun 2021, 490 patients aged 18 years and older were treated for moderate to severe COVID pneumonia. Out of these 490 patients, 132 patients had received first dose of covid-19 vaccine 14 days prior to onset of symptoms. Mortality happened in 55 patients out of which seven patients had received vaccine (p<0.05). Overall, there is very poor awareness regarding the type of covid-19 vaccine being administered to the patients. Conclusion: In conclusion, our findings from this study are that mortality or death rate is less observed in vaccinated patients when compared with unvaccinated patients. Older people, those with greater numbers of long-term conditions, people admitted to hospital in the recent weeks before their vaccination, people in high-risk occupations, care home residents, those from deprived backgrounds, men, and ex-smokers at the highest risk. By contrast, previous infection with COVID-19 was associated with a reduced risk of these events following vaccination. Overall, the rate of severe COVID-19 outcomes for individuals from 14 days onwards after a first dose of vaccine was very low, with less than 0.05% of people who received at least one vaccine suffering an adverse breakthrough event. None of the patients knew which vaccine they were administered, and neither had vaccine certificates also. We must emphasize the importance COVID 19 vaccines among Indian population.

Share this article